Mainz Biomed Amends Articles, Reduces Share Nominal Value

TL;DR

Mainz Biomed cut share nominal value to €0.01 and boosted authorized capital to €125k.

AI Summary

Mainz Biomed N.V. filed a Form 6-K on November 26, 2025, reporting a Deed of Amendment executed on November 13, 2025. Key changes include decreasing the nominal value of ordinary and preferred shares from €0.40 to €0.01 and increasing authorized share capital to €125,000, comprising 11,250,000 ordinary shares and 1,250,000 preferred shares.

Why It Matters

This amendment could impact the per-share accounting and market perception of Mainz Biomed's shares, potentially affecting future stock offerings or investor valuations.

Risk Assessment

Risk Level: low — This filing is a routine corporate update on share structure and does not indicate immediate financial distress or significant operational changes.

Key Numbers

• €0.01 — New Nominal Share Value (Reduced from €0.40 for ordinary and preferred shares.)
• €125,000 — Authorized Share Capital (Increased to this amount.)

Key Players & Entities

• MAINZ BIOMED N.V. (company) — Filer of the 6-K report
• €0.40 (dollar_amount) — Previous nominal value of ordinary and preferred shares
• €0.01 (dollar_amount) — New nominal value of ordinary and preferred shares
• €125,000 (dollar_amount) — New authorized share capital
• 11,250,000 (dollar_amount) — Number of ordinary shares authorized
• 1,250,000 (dollar_amount) — Number of preferred shares authorized
• November 13, 2025 (date) — Date of the Deed of Amendment
• November 26, 2025 (date) — Filing date of the 6-K report

FAQ

Filing Documents

• ea0266986-6k_mainz.htm (6-K) — 12KB
• ea026698601ex4-1_mainz.htm (EX-4.1) — 191KB
• 0001213900-25-115584.txt ( ) — 205KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File No. 001-41010 MAINZ BIOMED N.V. (Translation of registrant’s name into English) Robert Koch Strasse 50 55129 Mainz Germany (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F Form 40-F Deed of Amendment On November 13, 2025, we amended our Articles of Amendment by a Deed of Amendment. Among the primary changes to our Articles of Amendment were to: decrease the nominal value of our nominal value of our ordinary shares and preferred shares from €0.40 to €0.01; increase our authorized share capital to €125,000 divided into (i) 11,250,000 ordinary shares and 1,250,000 preferred shares (which will be increased into an authorized share capital of €500,000 divided into (i) 45,000,000 ordinary shares and (ii) 5,000,000 preferred shares if the number of outstanding ordinary shares exceeds 10,000,000); and eliminate the ability to issue fractional shares. The above description is qualified in its entirety by reference to the complete text of the English language translation of the Deed of Amendment attached as Exhibit 4.1 to this report, to our Articles of Association, as amended. Exhibit Index Exhibit No. Description 4.1 Unofficial English translation of Deed of Amendment, dated November 13, 2025 The information contained in this Report on Form 6-K is hereby incorporated by reference into our Registration Statement on Form F-3 (File No. 333-269091) and into the base prospectus and any prospectus supplement outstanding under the foregoing registration statement. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 26, 2025 By: /s/ William J. Caragol Chief Financial Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR